Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean countries [1]

Pediatric Blood and Cancer

Volumn 47, Issue 1, 2006, Pages 111-112

  Svarch, Eva ^a   Machín, Sergio ^a   Nieves, Rosa María ^b   Mancia De Reyes, Ana Gladys ^c   Navarrete, Marta ^d   Rodríguez, Hilze ^e  

^a INSTITUTO DE HEMATOLOGÍA E INMUNOLOGÍA   (Cuba)

^b School of Medicine   (Dominican Republic)

^c Hospital Nacional de Ninos Benjamin Bloom   (El Salvador)

^d HOSPITAL NACIONAL DE NIÑOS   (Costa Rica)

^e Hospital del Nino   (Panama)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA;

ACUTE CHEST SYNDROME; BLOOD VESSEL OCCLUSION; CHILD; COSTA RICA; CUBA; DOMINICAN REPUBLIC; DRUG EFFECT; DRUG EFFICACY; EL SALVADOR; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; PAINFUL VASOOCCLUSIVE CRISIS; PANAMA; PRIORITY JOURNAL; SICKLE CELL ANEMIA; STUDENT T TEST;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYUREA; RETROSPECTIVE STUDIES;

EID: 33646884665     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20823     Document Type: Letter

References (10)

1. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. N Eng J Med 1995;332:1317-1322.
2. Jayabose S, Tugal O, Sandoval C, et al. Clinical and hematological effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996;129:559-565.
3. Maier-Redelsperger M, Labie D, Elion J. Long term hydroxyurea treatment in young sickle cell patients. Curr Opin Hematol 1999;6:115-120.
4. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996;88:1960-1964.
5. Kinney TR, Helms RW, O'Bransky EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-Kids Study, a phase I/II trial. Blood 1999;94:1550-1554.
6. Zimmerman SA, Schultz WH, Davies JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103:2039-2045.
7. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001;97:3628-3632.
8. Masera G, Baez F, Biondi A, et al. Bridging the childhood cancer mortality gap between economically developed and low income countries: Lessons from the Mishpo experience. In: Tannenberg S, Cavalli F, Pannuti F, editors. In cancer in developing countries. The great challenge for oncology in the 21st century. Muenchen-Bern-Wien-New York, Zuckschwerdt: Verlag; 2004. pp 42-60.
9. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease, rates and risk factors. N Eng J Med 1991;325:11-16.
10. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Eng J Med 1994;330:1639-1644.